The role of myeloma cells to osteoclast activation

Yakhteh

Volumn 12, Issue 3, 2010, Pages 357-366

  Sadeghi, Bahareh ^a   Abroun, Saeid ^a   Poopak, Behzad ^b   Hajfathali, Abbas ^c   Saki, Najmeddin ^a   Vaghef, Najmeh ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone disease; Multiple myeloma; RANK; RANKL

Indexed keywords

MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTICLE; BONE REMODELING; CELL FUNCTION; CELL STRAIN; CELL STRAIN RPMI 8866; CELL STRAIN U 266; CELL STRAIN U937; CLINICAL ARTICLE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 78650432369     PISSN: 15614921     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Engelhardt M. Mertelsmann R. 160 years of multiple myeloma: Progress and challenges European Journal of Cancer 2006 42 11 1507-1509 DOI 10.1016/j.ejca.2006.05.003, PII S095980490600390X 1. Engelhardt M, Mertelsmann R. 160 years of Multiple Myeloma: progress and challenges. Eur J Cancer. 2006; 42: 1507-1509. (Pubitemid 44118777)
2. Lin P. Plasma cell neoplasms. Diagnostic Histopathology. 2009;15:134-141.
3. Edwards CM, Zhuang J, Mundy GR. The Pathogenesis of the bone disease of Multiple Myeloma. Bone. 2008; 42: 1007-1013.
4. Moser K, Tokoyoda K, Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 2006; 18(3): 265-270.
5. Esteve FR, Roodman GD.Pathophysiology of myeloma bone disease .Best Pract Res Clin Haematol. 2007; 20: 613-624.
6. Ashcroft A.J. Davies F.E. Morgan G.J. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma Lancet Oncology 2003 4 5 284-292 DOI 10.1016/S1470-2045(03)01076-3 6. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of biphosphanate in multiple myeloma. Lancet Oncol. 2003; 4: 284-292. (Pubitemid 36592496)
7. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation .Bone. 2007; 40: 251-264.
8. Del Fattore A, Teti A, Rucci N. Osteoclast receptors and signaling. Arch Biochem Biophys. 2008; 473: 147-160.
9. Jakob C, Sterz J, Zavreski I, Heider U, Kleeberg L, Fleissner C, et al. Angiogenesis in multiple myeloma. Eur J cancer. 2006; 42:1581-1590.
10. van Marion AMW, Lokhorst HM, van den Tweel JG. Pathology of Multiple Myeloma. Current Diagnostic Pathology. 2003; 9: 322-327.
11. Boyce BF, Xing L. Functions of RANKL/ RANK/ OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473:139-146.
12. Theoleyre S. Wittrant Y. Tat S.K. Fortun Y. Redini F. Heymann D. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling Cytokine and Growth Factor Reviews 2004 15 6 457-475 DOI 10.1016/j.cytogfr.2004.06.004, PII S1359610104000747 12. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK /RANKL : involvement in the orchestration of pathophysiological bone remodeling. Cytokine and Growth factor Rev. 2004; 15:457-475. (Pubitemid 39550455)
13. Armstrong A.P. Tometsko M.E. Glaccum M. Sutherland C.L. Cosman D. Dougall W.C. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function Journal of Biological Chemistry 2002 277 46 44347-44356 DOI 10.1074/jbc.M202009200 13. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for ostesclast cytoskeletal organization and resorptive function. J Biol Chem. 2002; 277: 44347-44356. (Pubitemid 36157870)
14. Anandarajah AP. Role of RANKL in bone diseases. Trends Endocrinol Metab. 2009 ; 20(2): 88-94.
15. Fouque-Aubert A, Chapurlat R. Influence of RANKL inhibition on immune diseases in the treatment of bone diseases. Joint Bone Spine. 2008; 75: 5-10.
16. Silvestris F. Lombardi L. De Matteo M. Bruno A. Dammacco F. Myeloma bone disease: Pathogenetic mechanisms and clinical assessment Leukemia Research 2007 31 2 129-138 DOI 10.1016/j.leukres.2006.04.014, PII S0145212606001469 16. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res. 2007; 31:129-138. (Pubitemid 44854187)
17. Seidl S. Kaufmann H. Drach J. New insights into the pathophysiology of multiple myeloma Lancet Oncology 2003 4 9 557-564 DOI 10.1016/S1470-2045(03) 01195-1, PII S1470204503011951 17. Seidl S, Kaufmann H, Drach J. New insights into the Pathophysiology of multiple myeloma. Lancet Oncol. 2003; 4: 557-564. (Pubitemid 38351713)
18. Kostenuik PJ. Osteoprotegrin and RANKL regulate bone resorption, density, geometry and strength. Curr opin Pharmacol. 2005; 5: 618-625.
19. Kearns A.E. Khosla S. Kostenuik P.J. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocrine Reviews 2008 29 2 155-192 http://edrv.endojournals.org/cgi/ reprint/29/2/155 DOI 10.1210/er.2007-0014 19. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine Reviews. 2008; 29(2): 155-192. (Pubitemid 351519689)
20. Soysa NS, Alles N. NF-KB functions in osteoclasts. Bioch Biophys Res commun. 2009; 378: 1-5.
21. Bommert K. Bargou R.C. Stuhmer T. Signalling and survival pathways in multiple myeloma European Journal of Cancer 2006 42 11 1574-1580 DOI 10.1016/j.ejca.2005.12.026, PII S0959804906003182 21. Bommert K, Bargou RC, Stühmer T. Signaling and survival pathway in multiple myeloma. Eur J Cancer. 2006; 42: 1574-1580. (Pubitemid 44118772)
22. De Leenheer E. Mueller G.S. Vanderkerken K. Croucher P.I. Evidence of a role for RANKL in the development of myeloma bone disease Current Opinion in Pharmacology 2004 4 4 340-346 DOI 10.1016/j.coph.2004.03.011, PII S1471489204000918 22. De Leenheer E, Mueller GS, Vanderkerken K, Croucher Pl. Evidence of a role for RANKL in the development of myeloma bone disease. Curr opin in Pharmacol. 2004; 4: 340-346. (Pubitemid 38987059)
23. Sezer O, Heider V, Jakob C, Eucker J, Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Oncol. 2002; 20(1): 353-354.
24. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin / osteoprotegerin ligand system in the human bone marrow enviroment. 2001; 98: 3527-3533.
25. Heider U, Langelotz C, Jakob C, Zavrski L, Fleissner C, Eucker J, et al. Expression of receptor activator of nuclear factor-KB ligand on bone marrow plasma cells correlates with multiple myeloma. Clinical cancer Res. 2003; 9: 1436-1440.